Literature DB >> 29217463

Electrical storm in the early phase of HeartMate® II device implantation: Incidence, risk factors and prognosis.

Jerome Corre1, François Picard2, Rodrigue Garcia3, Adlane Zemmoura3, Nicolas Derval3, Arnaud Denis4, Antoine Romen2, Karine Nubret2, Pierre Jais4, Michel Haissaguerre4, Pierre Dos Santos3, Laurent Barandon5, Frederic Sacher4.   

Abstract

BACKGROUND: Ventricular arrhythmia is common after left ventricular assist device (LVAD) implantation, especially in the early postoperative phase (<30 days). AIM: To identify the incidence of and risk factors for electrical storm (ES) occurring within 30 days of HeartMate® II implantation.
METHODS: We reviewed data from all consecutive patients undergoing HeartMate® II device implantation at our institution from January 2008 to December 2014. Patient demographic data, pharmacotherapies and outcomes were collected. The primary endpoint was occurrence of early ES (within 30 days of surgery), defined as three or more separate episodes of sustained ventricular arrhythmia within a 24-hour interval, requiring appropriate therapy.
RESULTS: Forty-three patients (mean age 56.7±11.2 years; 39 men) were included. At HeartMate® II implantation, mean left ventricular ejection fraction was 20±5%, 32 (74.4%) patients had ischaemic cardiomyopathy and 31 (72.1%) were implanted with an indication of bridge to cardiac transplantation. During follow-up, 12 (27.9%) patients experienced early ES after HeartMate® II implantation (median delay 9.1±7.8 days). Early ES was more frequent in larger patients (body surface area 1.99 vs 1.81 m2; P<0.01), tended to be associated with previous sustained ventricular tachycardia (50.0% vs 22.6%; P=0.08), previous implantable cardioverter-defibrillator implantation (66.7% vs 38.7%; P=0.09), discontinuation of long-term beta-blocker therapy (75.0% vs 45.2%; P=0.08), weaning of adrenergic drugs after the third day (66.7% vs 35.5%; P=0.06) and the use of extracorporeal life support (50% vs 22.6%; P=0.079), but was not associated with the cardiomyopathy aetiology or the indication for assistance. Catheter ventricular tachycardia ablation was performed in six (14.0%) patients. Early ES was associated with a significantly higher all-cause mortality rate at the 30th day (33.3% vs 6.5%; P=0.02).
CONCLUSION: ES is a common and pejorative feature in the early postoperative period.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Ablation endocardique de tachycardie ventriculaire; Arythmie ventriculaire; Assistance ventriculaire gauche; Electrical storm; Electromagnetic interference; Endocardial ventricular tachycardia ablation; HeartMate(®) II; Interférences électromagnétiques; Left ventricular assist device; Orage rythmique; Ventricular arrhythmia

Mesh:

Year:  2017        PMID: 29217463     DOI: 10.1016/j.acvd.2017.07.006

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  4 in total

Review 1.  Current Review of Implantable Cardioverter Defibrillator Use in Patients With Left Ventricular Assist Device.

Authors:  Jacinthe Boulet; Emmanuelle Massie; Blandine Mondésert; Yoan Lamarche; Michel Carrier; Anique Ducharme
Journal:  Curr Heart Fail Rep       Date:  2019-12

2.  Ventricular Tachycardia Ablation in Patients with Left Ventricular Assist Devices.

Authors:  Kaustubha D Patil; Jonathan Chrispin
Journal:  J Innov Card Rhythm Manag       Date:  2019-11-15

3.  A Review of New-Onset Ventricular Arrhythmia after Left Ventricular Assist Device Implantation.

Authors:  Jianwei Shi; Xinyi Yu; Zhigang Liu
Journal:  Cardiology       Date:  2022-04-28       Impact factor: 2.342

Review 4.  Ablation therapy for ventricular arrhythmias in patients with LVAD: Multiple faces of an electrophysiological challenge.

Authors:  Nicolò Sisti; Amato Santoro; Giovanni Carreras; Serafina Valente; Stefano Donzelli; Giulia Elena Mandoli; Carlotta Sciaccaluga; Matteo Cameli
Journal:  J Arrhythm       Date:  2021-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.